Solid Biosciences LLC (SLDB) - Total Assets
Based on the latest financial reports, Solid Biosciences LLC (SLDB) holds total assets worth $273.91 Million USD as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See what is Solid Biosciences LLC's book value for net asset value and shareholders' equity analysis.
Solid Biosciences LLC - Total Assets Trend (2015–2024)
This chart illustrates how Solid Biosciences LLC's total assets have evolved over time, based on quarterly financial data.
Solid Biosciences LLC - Asset Composition Analysis
Current Asset Composition (December 2024)
Solid Biosciences LLC's total assets of $273.91 Million consist of 83.4% current assets and 16.6% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 42.5% |
| Accounts Receivable | $0.00 | 0.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2015–2024)
This chart illustrates how Solid Biosciences LLC's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see SLDB stock market capitalisation.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Solid Biosciences LLC's current assets represent 83.4% of total assets in 2024, a decrease from 100.0% in 2015.
- Cash Position: Cash and equivalents constituted 42.5% of total assets in 2024, down from 51.3% in 2015.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2015.
- Asset Diversification: The largest asset category is goodwill at 0.0% of total assets.
Solid Biosciences LLC Competitors by Total Assets
Key competitors of Solid Biosciences LLC based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Fortress Biotech Inc
NASDAQ:FBIO
|
USA | $185.55 Million |
|
Summit Therapeutics PLC
NASDAQ:SMMT
|
USA | $261.73 Million |
|
Tubize-Fin
BR:TUB
|
Belgium | €1.93 Billion |
|
Apellis Pharmaceuticals Inc
NASDAQ:APLS
|
USA | $1.08 Billion |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161
|
China | CN¥16.55 Billion |
|
BrightGene Bio Medical Technology C
SHG:688166
|
China | CN¥5.38 Billion |
|
BioArctic AB (publ)
ST:BIOA-B
|
Sweden | Skr2.60 Billion |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
Solid Biosciences LLC - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 6.74 | 7.85 | 6.49 |
| Quick Ratio | 6.74 | 7.85 | 6.49 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $208.51 Million | $156.64 Million | $134.42 Million |
Solid Biosciences LLC - Advanced Valuation Insights
This section examines the relationship between Solid Biosciences LLC's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 2.17 |
| Latest Market Cap to Assets Ratio | 2.56 |
| Asset Growth Rate (YoY) | 14.4% |
| Total Assets | $188.66 Million |
| Market Capitalization | $482.26 Million USD |
Valuation Analysis
Premium Asset Valuation: The market values Solid Biosciences LLC's assets at a significant premium (2.56x), suggesting investors see substantial growth potential or unique competitive advantages.
Rapid Asset Growth: Solid Biosciences LLC's assets grew by 14.4% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Solid Biosciences LLC (2015–2024)
The table below shows the annual total assets of Solid Biosciences LLC from 2015 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $188.66 Million | +14.38% |
| 2023-12-31 | $164.94 Million | -36.62% |
| 2022-12-31 | $260.25 Million | +11.99% |
| 2021-12-31 | $232.38 Million | +35.76% |
| 2020-12-31 | $171.17 Million | +65.43% |
| 2019-12-31 | $103.47 Million | -25.88% |
| 2018-12-31 | $139.60 Million | +83.21% |
| 2017-12-31 | $76.19 Million | +87.50% |
| 2016-12-31 | $40.64 Million | -27.04% |
| 2015-12-31 | $55.70 Million | -- |
About Solid Biosciences LLC
Solid Biosciences Inc. develops therapies for neuromuscular and cardiac diseases in the United States. The company's lead product candidate is SGT-003, which is in phase 1/2 for the treatment of Duchenne muscular dystrophy. It also develops SGT-212 for the treatment of Friedreich's ataxia that is in phase 1b clinical trial; SGT-501 for the treatment of catecholaminergic polymorphic ventricular ta… Read more